iTonic Holdings Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.7M
- Price
- $0.2759
- % Change (Daily % change from the live per-ticker quote feed.)
- -11.94%
- Volume
- 1.6M
About
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Quick stats
Shares outstanding17.1M
Computed float9.3M
Float / shares54.7%
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001970544
Websitehttp://www.ftzy.com.cn
AI Summary
AI-generated1/35
minorneutrallegal litigation
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC
Robbins LLP is soliciting lead plaintiffs for a class action lawsuit against iTonic Holdings (ITOC), formerly Pheton Holdings, alleging a pump-and-dump scheme.
The complaint claims the stock price surged from $4.00 to $32.00 based on false rumors that Gilead Sciences (GILD) was acquiring the company, with impersonators posing as financial advisors.
This is a standard law-firm solicitation; the deadline to seek appointment as lead plaintiff is September 28, 2026.